Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients

Ashokkumar Jain, Raman Venkataramanan, Rajeev Sharma, Tai Kwong, Peter Abt, Mark Orloff, Randeep Kashyap, Georgious Tsoulfas, Adel Bozorgzadeh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The exposure of mycophenolic acid in live donor liver transplant patients (those receiving a partial hepatic volume) in comparison to deceased donor liver transplant patients (those receiving the whole hepatic volume) after administration of mycophenolate mofetil has not been reported earlier. The aim of the present study is to compare the pharmacokinetics parameters of mycophenolic acid and mycophenolic acid glucuronide in live donor liver transplant patients versus deceased donor liver transplant patients. Twelve live donor liver transplant and 12 deceased donor liver transplant recipients were studied over a dosing interval after intravenous administration of mycophenolate mofetil. The maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) for mycophenolic acid in live donor liver transplant patients were significantly higher than in deceased donor liver transplant patients (Cmax/AUC: live donor liver transplant patients: 16.1 ± 6.6 μg/mL/43.9 ± 12.6 μg/mL·h vs deceased donor liver transplant patients: 10.7 ± 2.0 μg/mL/28.9 ± 7.1 μg/mL·h; P =.046/.002). The volume of distribution was higher in the deceased donor liver transplant patients compared with live donor liver transplant patients. However, the mean plasma concentration at 12 hours (Clast), drug disposition rate constant, half-life (t1/2), and mean residence time were similar in both groups. The mean plasma concentration of mycophenolic acid glucuronide was 1.4 to 2.0 times higher in deceased donor liver transplant patients compared with live donor liver transplant patients. These observations point to the need to use a lower dosage (approximately 30%) of mycophenolate mofetil in live donor liver transplant patients compared with deceased donor liver transplant patients.

Original languageEnglish (US)
Pages (from-to)547-552
Number of pages6
JournalJournal of Clinical Pharmacology
Volume48
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Mycophenolic Acid
Pharmacokinetics
Tissue Donors
Transplants
Liver
Area Under Curve

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Jain, Ashokkumar ; Venkataramanan, Raman ; Sharma, Rajeev ; Kwong, Tai ; Abt, Peter ; Orloff, Mark ; Kashyap, Randeep ; Tsoulfas, Georgious ; Bozorgzadeh, Adel. / Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. In: Journal of Clinical Pharmacology. 2008 ; Vol. 48, No. 5. pp. 547-552.
@article{3df004a2b422406ba71de186b067c139,
title = "Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients",
abstract = "The exposure of mycophenolic acid in live donor liver transplant patients (those receiving a partial hepatic volume) in comparison to deceased donor liver transplant patients (those receiving the whole hepatic volume) after administration of mycophenolate mofetil has not been reported earlier. The aim of the present study is to compare the pharmacokinetics parameters of mycophenolic acid and mycophenolic acid glucuronide in live donor liver transplant patients versus deceased donor liver transplant patients. Twelve live donor liver transplant and 12 deceased donor liver transplant recipients were studied over a dosing interval after intravenous administration of mycophenolate mofetil. The maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) for mycophenolic acid in live donor liver transplant patients were significantly higher than in deceased donor liver transplant patients (Cmax/AUC: live donor liver transplant patients: 16.1 ± 6.6 μg/mL/43.9 ± 12.6 μg/mL·h vs deceased donor liver transplant patients: 10.7 ± 2.0 μg/mL/28.9 ± 7.1 μg/mL·h; P =.046/.002). The volume of distribution was higher in the deceased donor liver transplant patients compared with live donor liver transplant patients. However, the mean plasma concentration at 12 hours (Clast), drug disposition rate constant, half-life (t1/2), and mean residence time were similar in both groups. The mean plasma concentration of mycophenolic acid glucuronide was 1.4 to 2.0 times higher in deceased donor liver transplant patients compared with live donor liver transplant patients. These observations point to the need to use a lower dosage (approximately 30{\%}) of mycophenolate mofetil in live donor liver transplant patients compared with deceased donor liver transplant patients.",
author = "Ashokkumar Jain and Raman Venkataramanan and Rajeev Sharma and Tai Kwong and Peter Abt and Mark Orloff and Randeep Kashyap and Georgious Tsoulfas and Adel Bozorgzadeh",
year = "2008",
month = "5",
day = "1",
doi = "10.1177/0091270008315317",
language = "English (US)",
volume = "48",
pages = "547--552",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "5",

}

Jain, A, Venkataramanan, R, Sharma, R, Kwong, T, Abt, P, Orloff, M, Kashyap, R, Tsoulfas, G & Bozorgzadeh, A 2008, 'Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients', Journal of Clinical Pharmacology, vol. 48, no. 5, pp. 547-552. https://doi.org/10.1177/0091270008315317

Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. / Jain, Ashokkumar; Venkataramanan, Raman; Sharma, Rajeev; Kwong, Tai; Abt, Peter; Orloff, Mark; Kashyap, Randeep; Tsoulfas, Georgious; Bozorgzadeh, Adel.

In: Journal of Clinical Pharmacology, Vol. 48, No. 5, 01.05.2008, p. 547-552.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients

AU - Jain, Ashokkumar

AU - Venkataramanan, Raman

AU - Sharma, Rajeev

AU - Kwong, Tai

AU - Abt, Peter

AU - Orloff, Mark

AU - Kashyap, Randeep

AU - Tsoulfas, Georgious

AU - Bozorgzadeh, Adel

PY - 2008/5/1

Y1 - 2008/5/1

N2 - The exposure of mycophenolic acid in live donor liver transplant patients (those receiving a partial hepatic volume) in comparison to deceased donor liver transplant patients (those receiving the whole hepatic volume) after administration of mycophenolate mofetil has not been reported earlier. The aim of the present study is to compare the pharmacokinetics parameters of mycophenolic acid and mycophenolic acid glucuronide in live donor liver transplant patients versus deceased donor liver transplant patients. Twelve live donor liver transplant and 12 deceased donor liver transplant recipients were studied over a dosing interval after intravenous administration of mycophenolate mofetil. The maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) for mycophenolic acid in live donor liver transplant patients were significantly higher than in deceased donor liver transplant patients (Cmax/AUC: live donor liver transplant patients: 16.1 ± 6.6 μg/mL/43.9 ± 12.6 μg/mL·h vs deceased donor liver transplant patients: 10.7 ± 2.0 μg/mL/28.9 ± 7.1 μg/mL·h; P =.046/.002). The volume of distribution was higher in the deceased donor liver transplant patients compared with live donor liver transplant patients. However, the mean plasma concentration at 12 hours (Clast), drug disposition rate constant, half-life (t1/2), and mean residence time were similar in both groups. The mean plasma concentration of mycophenolic acid glucuronide was 1.4 to 2.0 times higher in deceased donor liver transplant patients compared with live donor liver transplant patients. These observations point to the need to use a lower dosage (approximately 30%) of mycophenolate mofetil in live donor liver transplant patients compared with deceased donor liver transplant patients.

AB - The exposure of mycophenolic acid in live donor liver transplant patients (those receiving a partial hepatic volume) in comparison to deceased donor liver transplant patients (those receiving the whole hepatic volume) after administration of mycophenolate mofetil has not been reported earlier. The aim of the present study is to compare the pharmacokinetics parameters of mycophenolic acid and mycophenolic acid glucuronide in live donor liver transplant patients versus deceased donor liver transplant patients. Twelve live donor liver transplant and 12 deceased donor liver transplant recipients were studied over a dosing interval after intravenous administration of mycophenolate mofetil. The maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) for mycophenolic acid in live donor liver transplant patients were significantly higher than in deceased donor liver transplant patients (Cmax/AUC: live donor liver transplant patients: 16.1 ± 6.6 μg/mL/43.9 ± 12.6 μg/mL·h vs deceased donor liver transplant patients: 10.7 ± 2.0 μg/mL/28.9 ± 7.1 μg/mL·h; P =.046/.002). The volume of distribution was higher in the deceased donor liver transplant patients compared with live donor liver transplant patients. However, the mean plasma concentration at 12 hours (Clast), drug disposition rate constant, half-life (t1/2), and mean residence time were similar in both groups. The mean plasma concentration of mycophenolic acid glucuronide was 1.4 to 2.0 times higher in deceased donor liver transplant patients compared with live donor liver transplant patients. These observations point to the need to use a lower dosage (approximately 30%) of mycophenolate mofetil in live donor liver transplant patients compared with deceased donor liver transplant patients.

UR - http://www.scopus.com/inward/record.url?scp=41849098067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849098067&partnerID=8YFLogxK

U2 - 10.1177/0091270008315317

DO - 10.1177/0091270008315317

M3 - Article

C2 - 18440919

AN - SCOPUS:41849098067

VL - 48

SP - 547

EP - 552

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 5

ER -